Hypothesis
A personalized fasting regimen, calibrated to an individual's baseline MileAge and tissue‑specific metabolomic signatures, will produce greater autophagic flux (measured by LC3‑II/I ratio in circulating extracellular vesicles) and improve cardiovascular fitness (VO₂ Max) and lipid profile (ApoB < 80 mg/dL) without accelerating telomere attrition compared to a standard 24‑hour intermittent fasting schedule.
Mechanistic Rationale
It's known that prolonged fasting activates AMPK‑ULK1 and SIRT2‑ATG4B pathways, driving autophagy after ~24 h, while mTOR inhibition sustains the response up to 48 h [1][2]. However, AMPK versus SIRT2 dominance remains debated, and tissue‑specific responses vary widely [3][4]. MileAge, a plasma NMR‑derived metabolomic clock, predicts mortality better than many traditional biomarkers [5] and reflects metabolic aging that likely correlates with cellular nutrient‑sensing capacity. We propose that individuals with a high MileAge delta (i.e., biologically older metabolism) possess a blunted AMPK response but retained SIRT2 activity, making them responsive to fasting protocols that emphasize SIRT2‑mediated LC3 processing (e.g., longer fasts with modest calorie density). Conversely, those with low MileAge may rely more on AMPK‑ULK1 activation and benefit from shorter, more frequent fasts.
Nutrient‑dense caloric restriction improves insulin sensitivity and reduces visceral fat, yet early telomere loss suggests a stress‑response trade‑off [9][10][11]. By aligning fasting duration with MileAge‑guided AMPK/SIRT2 balance, we hypothesize that





























